195 related articles for article (PubMed ID: 32571982)
1. NRF2-Driven
Tian Y; Liu Q; Yu S; Chu Q; Chen Y; Wu K; Wang L
Mol Cancer Res; 2020 Oct; 18(10):1465-1476. PubMed ID: 32571982
[TBL] [Abstract][Full Text] [Related]
2. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer.
Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L
J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
6. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
Zeng H; Zhao X; Tang C
Cancer Chemother Pharmacol; 2021 Aug; 88(2):223-233. PubMed ID: 33907880
[TBL] [Abstract][Full Text] [Related]
8. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
9. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
11. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
12. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
13. Expression of Nrf2-Keap1-ARE signal pathway in traumatic lung injury and functional study.
Hu LY; Cui JB; Xu XM; Huang ZH; Jiao HT
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1402-1408. PubMed ID: 29565500
[TBL] [Abstract][Full Text] [Related]
14. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
[TBL] [Abstract][Full Text] [Related]
15. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
16. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
17. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
18. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
[TBL] [Abstract][Full Text] [Related]
19. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
